Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

European Commission Expands Ravulizumab-cwvz Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication

September 3rd 2021

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

Neoadjuvant Cabozantinib/Nivolumab Leads to Improved Resection Rates in HCC

September 2nd 2021

The combination of cabozantinib and nivolumab as a neoadjuvant regimen led to encouraging margin-negative resection and major pathological response rates in patients with hepatocellular carcinoma, according to results of a single-arm, phase 1b study that were published in Nature Cancer.

FDA Grants Orphan Drug Status to Gavocabtagene Autoleucel for Cholangiocarcinoma

September 2nd 2021

The FDA has granted an orphan drug designation to gavocabtagene autoleucel as a potential treatment for patients with cholangiocarcinoma.

Pevonedistat/Azacitidine Misses EFS End Point in Frontline Higher-Risk MDS/CMML, Low-Blast AML

September 2nd 2021

The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.

Zanidatamab Plus Tucatinib/Capecitabine Is Being Tested in Advanced HER2+ Breast Cancer

September 1st 2021

Zanidatamab is being combined with tucatinib and capecitabine in a new cohort of a phase 1 trial of patients with locally advanced and/or metastatic HER2-positive breast cancer.

Berzosertib/Chemo Combo Misses PFS End Point in Metastatic Urothelial Cancer

August 31st 2021

The addition of berzosertib to standard cisplatin/gemcitabine did not improve progression-free survival compared with chemotherapy alone in patients with metastatic urothelial cancer.

ASTRO Guideline Provides Clarity on Radiation Use in Soft Tissue Sarcoma

August 30th 2021

The American Society for Radiation Oncology released a new clinical guideline, which was also published in Practical Radiation Oncology, outlined recommendations and patient selection for optimal radiation dosing, sequencing, and treatment planning for patients with soft tissue sarcoma.

Ibrutinib Shows Continued Activity in Relapsed, Variant-Type Hairy Cell Leukemia

August 27th 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

SY-5609 Under Investigation With Atezolizumab in Colorectal Cancer Subsets

August 25th 2021

The highly selective and potent CDK7 inhibitor SY-5609 is being tested in combination with atezolizumab in patients with molecularly defined subsets of colorectal cancer, as one of the cohorts of the ongoing, phase 1/1b INTRINSIC trial.

Population-Based Data Show Amputations in Malignant Foot Neoplasms Correlate With Hispanics, Males

August 24th 2021

Amputations were found to be associated with Hispanic ethnicity and male sex in patients with neoplasms of the foot.

Transvaginal Ultrasound Misses Mark on Screening Endometrial Cancer in Black Women

August 20th 2021

The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.

Average Cumulative Relative Adjuvant Chemo Dose Linked With Survival in CRC

August 17th 2021

Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.

Checkpoint Inhibitor/TKI Combos Jump RCC Treatment to Next Level

August 9th 2021

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC

July 12th 2021

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Sequential Mitomycin/BCG Combo Shows Preliminary Safety in High-Risk NMIBC

July 10th 2021

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

ctDNA Positivity Linked With Inferior DFS in Stage I to IV Colorectal Cancer

July 7th 2021

Longitudinal circulating tumor DNA positivity detected at 4, 12, and 24 weeks after surgery in patients with stage I to IV colorectal cancer was significantly associated with inferior disease-free survival.

FDA Approves Rylaze for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

June 30th 2021

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.

Phase 1 CYNK-001 Trial Expands to Include Relapsed/Refractory AML Population

June 29th 2021

A phase 1 study evaluating the off-the-shelf cell therapy CYNK-001 has expanded to include patients with relapsed/refractory acute myeloid leukemia after a case of conversion to minimal residual disease negativity at its highest dose level.

Cemiplimab Approved in Europe for PD-L1+ NSCLC, Basal Cell Carcinoma

June 25th 2021

The European Commission has granted approval to cemiplimab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumor cells have at least 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations and are ineligible for definitive chemoradiation.